Healthcare
Live Price
Offline$55.15
+1.87% today
Window Change
+16.89%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Travere Therapeutics, Inc. (TVTX) is a Healthcare stock with a market cap of $4.08B and listed on NASDAQ. The stock last traded around $55.15 and up 16.9% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +110.5%, EPS growth of +86.3%, a dividend yield of 0.0%. What stands out right now is revenue +110.5%, EPS +86.3%, free cash flow +111.2% with operating margin -12.8% and ROIC -13.9%. Valuation already assumes a fairly strong business story at price/sales 8.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TVTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TVTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TVTX Max Drawdown
-8.94%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TVTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$131.8M
+20.4% YoY
FY Net Income
-$180.1M
+35.3% YoY
Free Cash Flow
-$38.9M
+81.9% YoY
Revenue Growth
+110.5%
EPS Growth
+86.3%
Gross Margin
94.2%
Net Margin
-10.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 491M | 233M | 145M | 109M | 132M |
| Gross Profit | 420M | 225M | 134M | 105M | 128M |
| Operating Income | -63M | -324M | -388M | -320M | -199M |
| EBITDA | 22M | -266M | -326M | -299M | -184M |
| Net Income | -50M | -322M | -111M | -278M | -180M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 93M | 59M | 58M | 62M | 166M |
| Total Assets | 605M | 594M | 789M | 673M | 777M |
| Total Liabilities | 490M | 535M | 588M | 630M | 475M |
| Shareholder Equity | 115M | 59M | 201M | 43M | 302M |
| Total Debt | 329M | 402M | 405M | 407M | 262M |
| Net Debt | 236M | 343M | 347M | 346M | 96M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15M
+92.1% YoY
Capital Expenditures
24M
+14.9% YoY
Free Cash Flow
39M
+81.9% YoY
Key ratios
Gross Margin
94.2%
Operating Margin
-12.8%
Net Margin
-10.2%
ROE
-79.2%
Debt / Equity
2.96x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.